Bio-Rad Laboratories, Inc. Class A Common Stock vs Uber Technologies Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Uber Technologies Inc trades at $72.5 (market cap $146.73B). The key difference: Uber Technologies Inc is far larger — about 18.3× Bio-Rad Laboratories, Inc. Class A Common Stock's market cap, and Bio-Rad Laboratories, Inc. Class A Common Stock is trading nearer its 52-week high, Uber Technologies Inc nearer its low. Which is the better fit depends on your goals.
| BIO | UBER | |
|---|---|---|
Market Cap | $8.04B | $146.73B |
Sector | Health | Industrials |
52-Week High | $339.75 | $100.10 |
52-Week Low | $241.71 | $68.61 |
Enterprise Value | $7.85B | $153.05B |
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
Uber Technologies (UBER) trades at $74.26, down 0.38% on the day, with strong analyst consensus of 49 buys and 0 sells. The stock shows bullish technical signals with moving averages supporting upward momentum. Fundamentally, Uber demonstrates robust revenue growth from $31.9B in 2022 to $52.0B in 2025, though net income margin has moderated from 22.41% to 19.32%. Recent developments include strategic moves into autonomous vehicles with partnerships in Spain and Germany.
Uber presents a compelling growth story with expanding profitability and dominant market position. The 36% upside to consensus price target of $108.92 suggests significant potential. Key risks include execution challenges in autonomous vehicle rollout, competitive pressures in key markets like India, and potential margin compression. Operating cash flow strength at $10.1B supports continued investment in growth initiatives.
Trailing returns across standard periods
Latest headlines on both assets
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →Uber Technologies is a technology provider that matches riders with drivers, hungry people with restaurants and food delivery service providers, and shippers with carriers. The firm's on-demand technology platform could eventually be used for additional products and services, such as autonomous vehicles, delivery via drones, and Uber Elevate, which, as the firm refers to it, provides aerial ride-sharing. Uber Technologies is headquartered in San Francisco and operates in over 63 countries with over 110 million users that order rides or foods at least once a month. Approximately 76% of its gross revenue comes from ride-sharing and 22% from food delivery.
Read more on UBER →